ArticleHuman vaccines & immunotherapeutics2026
Health-related quality of life and adverse events during 14 days after receiving a live-attenuated influenza vaccine in Japanese children 4-15 years of age.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
No data have been collected regarding the quality of life after live-attenuated influenza vaccine (LAIV). Our study investigates LAIV's impact on the quality of life of children. This prospective, questionnaire-based study targeted children aged 4-15 y. Guardians responded to daily surveys for 16 d, starting the day before vaccination. The questionnaire included the EuroQoL 5-dimension Youth 3-Level (EQ-5D-Y-3L) tool and the EuroQoL Visual Analogue Scale (EQ-VAS) monitoring fluctuations of health-related quality of life (HRQL) and adverse events following immunization (AEFIs). Time series analysis and area under the curve (AUC) calculation were used to investigate the scores' changes. Final analysis involved 92 patients who responded to at least half of the questionnaire's iterations, including both day 7 and 14 after vaccination. One or more AEFIs were reported for 78 children (73.91%), with generally mild symptoms. In 30 cases, a significant impact on daily activities was described, and one serious AEFI was reported consisting of severe headache and pharyngodynia with fever, leading to emergency room access. EQ-VAS score dropped on the first 2 d after vaccination and recovered thereafter, reaching (and even exceeding) the pre-vaccination value on day 10. The EQ-5D-Y-3L score also declined, however, only on day 1 and recovered faster, reaching the pre-vaccination value already on day 5, undulating around the baseline level until day 10. A net loss of 0.01 quality-adjusted life days was identified (AUC: -0.0138). Our analysis showed a positive LAIV safety profile. Data from larger populations are needed to support clinical recommendations, promoting vaccine acceptance and fighting hesitancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.